Last quarter (Q ), ImmunityBio's total revenue was $139.00K, an increase of 90.41% from the same quarter last year. In Q, ImmunityBio's net income was $-233.39M. See ImmunityBio’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20
Total Revenue	$ 622.00K	$ 622.00K	$ 240.00K	$ 934.00K	$ 605.00K
Cost of Revenue	-	-	-	-	-
Gross Profit	$ 622.00K	$ 622.00K	$ 240.00K	$ 934.00K	-
Operating Expense	$ 362.87M	$ 362.87M	$ 351.54M	$ -331.21M	$ 210.82M
Operating Income	$ -362.25M	$ -362.25M	$ -351.30M	$ -330.28M	$ -210.22M
Net Non Operating Interest Income Expense	$ -129.20M	$ -129.20M	$ -63.52M	$ -14.85M	$ -7.35M
Other Income Expense	$ 93.33M	$ 93.33M	$ 3.15M	$ 4.71M	$ -8.46M
Pretax Income	$ -583.89M	$ -583.89M	$ -417.29M	$ -349.84M	$ -226.03M
Tax Provision	$ -40.00K	$ -40.00K	$ 34.00K	$ 9.00K	$ -1.85M
Earnings From Equity Interest Net Of Tax	$ -7.55M	$ -7.55M	$ -12.11M	$ -803.00K	-
Net Income Common Stockholders	$ -583.20M	$ -583.20M	$ -416.57M	$ -346.79M	$ -221.85M
Basic EPS	$ -1.13	$ -1.15	$ -1.04	$ -0.89	$ -0.58
Diluted EPS	$ -1.13	$ -1.15	$ -1.04	$ -0.89	$ -0.58
Basic Average Shares	$ 2.03B	$ 508.64M	$ 399.90M	$ 389.23M	$ 383.18M
Diluted Average Shares	$ 2.03B	$ 508.64M	$ 399.90M	$ 389.23M	$ 383.18M
Dividend Per Share	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-
Total Expenses	$ 362.87M	$ 362.87M	$ 351.54M	$ -331.21M	$ 210.82M
Net Income From Continuing And Discontinued Operation	$ -583.44M	$ -583.20M	$ -416.57M	$ -346.79M	$ -221.85M
Normalized Income	$ -417.35M	$ -583.05M	$ -329.97M	-	$ -212.83M
Interest Expense	-	-	-	-	$ 9.07M
EBIT	$ -454.69M	$ -454.69M	$ -389.21M	$ -337.10M	$ -216.96M
EBITDA	$ -300.44M	$ -387.81M	$ -347.42M	$ -317.51M	$ -204.22M

Currency in USD

ImmunityBio Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing